Introduction {#s1}
============

Imatinib has revolutionised the treatment for cancer and led to a subsequent discovery of a class of drugs known as small molecule kinase inhibitors ([@B92]). It is approved as the first-line treatment for chronic myeloid leukaemia (CML) and gastrointestinal stromal tumours (GIST) in adult patients and for CML and Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukaemia (ALL) in children and adolescents ([@B101]). A phase III clinical trial highlighted that imatinib was well tolerated and effective for newly diagnosed paediatric CML, with a 5-year progression free survival of 94% ([@B102]). A 5-year follow-up of imatinib (340 mg/m^2^/d) in combination with conventional chemotherapy drugs (e.g., cyclophosphamide, methotrexate, and cytarabine) showed a favorable outcome in children with Ph+ ALL, similar to that of bone marrow transplantation ([@B98]).

The prevalence of childhood CML and Ph+ ALL, however, is very low, accounting for around 2% of all leukaemias and 3%--5% of ALL in children, respectively ([@B25]). Therefore, an optimal dose for imatinib in paediatric patients, let alone its potential drug-drug interactions, has been less widely explored. Imatinib is mainly metabolised by cytochrome P450 (CYP)3A4 and CYP2C8 ([@B10]), and thus, has a potential for drug interactions with modulators of these CYP enzymes. A clinically significant interaction between imatinib and carbamazepine, a CYP3A and CYP2C8 inducer, was described in a 12-year old CML patient with epilepsy ([@B103]). However, little is known about imatinib interactions with other potential perpetrator drugs in paediatric patients. Conducting a dedicated clinical interaction study in paediatric population remains challenging owing to the ethical and logistical constraints ([@B8]). Clearly, a feasible and systematic approach to address this gap is warranted.

Physiologically based pharmacokinetic (PBPK) modeling can account for anatomical and physiological growth and organ maturation underlying age-related changes in the pharmacokinetics of a drug of interest ([@B113]). This facilitates an extrapolation across the age spectrum ([@B66]). The PBPK approach has been increasingly embraced by regulatory authorities for the purposes of informing dose selection, providing simulation-based trial design and investigating potential drug interactions in paediatric populations ([@B26]; [@B15]). According to applications related to PBPK that were submitted to the US Food and Drug Administration (FDA) from 2008 to 2017, PBPK analyses are mainly intended for evaluating and predicting enzyme-based drug interactions (60% of all applications), followed by utilization in paediatric area (15%) ([@B47]). PBPK modeling and simulation has been an integral part of drug development for paediatric cancers ([@B90]). PBPK models which can capture developmental changes in biological components are useful in describing in paediatrics the pharmacokinetics of anticancer drugs, including etoposide ([@B62]), busulfan ([@B31]), docetaxel ([@B104]), actinomycin D ([@B109]) and nilotinib ([@B50]).

A PBPK model for imatinib that incorporates maturational changes of key drug-metabolising enzymes and age-dependent organ development can help inform optimal dose selection in children. PBPK modeling and simulation also provides a greater understanding of potential drug interactions with imatinib in this vulnerable patient group which remains largely unexplored. The aim of this study was to develop and implement a paediatric PBPK model of imatinib for investigating optimal dosing regimens in children and the vulnerability to drug interactions relative to adults with a range of CYP3A modulators.

Methods {#s2}
=======

In this study, a PBPK model for imatinib was developed and verified in adults and subsequently extrapolated to children and adolescents (aged 2--18 years). The verified PBPK model was then implemented to explore optimal dosing regimens for imatinib in children and to evaluate potential drug interactions with CYP3A modulators. The workflow of this study is summarized in [**Figure 1**](#f1){ref-type="fig"}.

![Schematic representation of workflow of this study. Physiologically based pharmacokinetic (PBPK) model of imatinib in adults was constructed using drug-dependent and system-related input parameters and verified using published clinical pharmacokinetic data. The verified model was subsequently extrapolated to children and adolescents by incorporating age-related changes in organ size and maturation of cytochrome P450 (CYP)3A4 and CYP2C8 and α~1~-acid glycoprotein and then verified to clinically observed concentrations in paediatric population. Paediatric PBPK model of imatinib was implemented to determine an optimal dosing regimen for imatinib and evaluate potential drug interactions with a range of CYP3A modulators in children older than 2 years.](fphar-10-01672-g001){#f1}

Development and Verification of a PBPK Model for Imatinib in Adults {#s2_1}
-------------------------------------------------------------------

All population-based PBPK modeling and simulations were conducted using the Simcyp Simulator (version 17 release 1, Certara UK Limited, Simcyp Division, Sheffield, UK) using the "general North European Caucasian" population library data, which represents typical healthy adult people from European ancestry. The description of Simcyp Simulator workflow, basic algorithm, and ordinary differential equations have been detailed previously ([@B93]; [@B54]). The drug-related input parameters for imatinib are listed in [**Table 1**](#T1){ref-type="table"}.

###### 

Drug-related parameters used to build a physiologically based pharmacokinetic (PBPK) model for imatinib in Simcyp Simulator.

  Parameter                                                 Value                        Source
  --------------------------------------------------------- ---------------------------- ----------------------------------------------------------------------------------------------------------
  **Physicochemical and blood-binding properties**                                       
  Molecular weight                                          493.6                        PubChem[^a)^](#fnT1_1){ref-type="table-fn"}
  Log P~o:w~                                                1.99                         ([@B84])
  Ionisation pattern                                        Diprotic base                PubChem and ChEMBL[^b)^](#fnT1_2){ref-type="table-fn"}
  pKa                                                       8.07; 3.73                   
  B/P                                                       0.73                         ([@B65])
  fu~p~                                                     0.05                         ([@B100])
  Plasma binding component                                  α~1~-acid-glycoprotein       
  **Absorption phase**                                                                   
  Model                                                     ADAM model                   ([@B29])
  P~eff~ (10^-4^ cm.s^-1^)                                  0.92                         Predicted in Simcyp Simulator
  fu~G~                                                     1                            Assumed ([@B111])
  Q~Gut~ (L.h^-1^)                                          6.04                         Predicted in Simcyp Simulator
  **Distribution phase**                                                                 
  Prediction method                                         Rodgers and Rowland method   ([@B91])
  V~ss~ (L.kg^-1^)                                          1.8                          Predicted in Simcyp Simulator
  **Elimination phase**                                                                  
  Pathway 1                                                 CYP3A4 (NDMI formation)      
  V~max~ (pmol.min^-1^.pmol CYP^-1^)                        3.0                          Estimated from an *in vitro* study in recombinant CYP3A4
  K~m~ (µmol.L^-1^)                                         10.54                        
  fu~inc~                                                   0.96                         Predicted in Simcyp Simulator
  ISEF                                                      0.21                         ([@B22])
  Pathway 2                                                 CYP2C8 (NDMI formation)      
  V~max~ (pmol.min^-1^.mg protein^-1^)                      56.4                         *In vitro* study in HLM of which CYP3A4 enzyme was inactivated by azamulin
  K~m~ (µmol.L^-1^)                                         7.49                         
  fu~inc~                                                   0.97                         Predicted in Simcyp Simulator
  Pathway 3                                                 CYP3A4 (other metabolites)   
  CL~int~ (µl.min^-1^.mg protein^-1^)                       33.4                         Estimated from imatinib depletion in recombinant CYP3A4
  fu~inc~                                                   1                            
  Pathway 4                                                 CYP2C8 (other metabolites)   
  CL~int~ (µl.min^-1^.mg protein^-1^)                       24.2                         Calculated from subtraction of *in vivo* CL/F ([@B110]) to the sum of scaled CL~int~ from other pathways
  fu~inc~                                                   1                            
  CL~R~ (L.h^-1^)                                           0.5                          ([@B18])
  Additional HLM CL~int~ (µl.min^-1^.mg protein^-1^)        31                           Compensatory clearance for autoinhibition of CYP3A4 at steady-state
  **Drug transport -- hepatobiliary transporters**                                       
  Pathway 1                                                 ABCB1                        
  CL~int,T~ (µl.min^-1^.million cells^-1^)                  1.5                          Calculated from P~eff~ data in ABCB1-transfected MDCK II cells ([@B28])
  RAF                                                       1                            
  Pathway 2                                                 ABCG2                        
  J~max~ (pmol.min^-1^.million cells^-1^)                   89.4                         Estimated from *in vitro* transport data ([@B19])
  K~m~ (µmol.L^-1^)                                         4.37                         
  RAF                                                       0.38                         Estimated from *in vivo* biliary clearance of imatinib ([@B48])
  CL~PD~ (ml.min^-1^.million hepatocytes^-1^)               0.2                          Assumed
  **Drug interactions** (for multiple-dosing of imatinib)                                
  Mechanism-based inhibition                                                             
  k~inact,~ ~CYP3A~ (h^-1^)                                 4.29                         ([@B37])
  K~I~ (µmol.L^-1^)                                         14.3                         
  f~u,inc~                                                  0.8                          

ABCB1, multidrug resistance protein 1 or p-glycoprotein; ADAM, advanced dissolution, absorption and metabolism; B/P, blood to plasma ratio; CL~int~, hepatic intrinsic clearance; CL~int,T~, transporter-mediated intrinsic clearance; CL~PD~, passive diffusion clearance; CL~R~, renal clearance; fu~inc~, unbound fraction during incubation; fu~G~, unbound fraction in the enterocytes; fu~p~, unbound fraction in plasma; HLM, human liver microsomes; ISEF, intersystem extrapolation factor; J~max~, maximum flux of a substrate across a drug transporter; K~I~, the concentration that provides half of k~inact~; k~inact~, maximum inactivation rate of CYP enzyme; K~m~, substrate concentration giving half of V~max~ or J~max~; Log P~o:w~, the partition coefficient in oil and water; MDCKII, Madine-Darby canine kidney cells; NDMI, N-desmethyl imatinib; P~eff~, the effective intestinal permeability; pKa, negative logarithm of acid dissociation constant; Q~Gut~, the gut blood flow rate; RAF, relative activity factor; V~max~, maximum rate of reaction; V~ss~, volume of distribution at steady-state based on total tissue volumes.

Accessed from pubchem.ncbi.nlm.gov.

Accessed from ebi.ac.uk/chembl.

As a basic compound, imatinib binds extensively to α~1~-acid glycoprotein (AAG) ([@B65]) with an unbound fraction (fu~p~) of 0.05 ([@B100]). A higher level of AAG has been reported in patients with solid tumours ([@B104]). However, plasma AAG concentration is similar in healthy people when compared to patients with CML and GIST (mean value of 0.81 vs. 0.79--1.08 and 0.89 g/L, respectively) ([@B40]; [@B41]; [@B49]; [@B16]). This corresponded to an unbound fraction in plasma (fu~p~) for imatinib which was not dissimilar, yet highly variable, between healthy people \[0.05 (range 0.02--0.10)\] and patients with CML \[0.03 (range 0.01--0.10)\] ([@B100]; [@B41]). Interestingly, AAG concentrations in patients with GIST were relatively stable over a 1-year course of treatment with imatinib ([@B16]). Thus, a fixed fu~p~ of 0.05 with associated variability was assigned to adult population. There is a paucity of data on AAG concentration in paediatrics with CML. Nevertheless, clinical data in children with Ph+ ALL (n = 4, aged 6--15 years) hinted at a similar AAG concentration (mean ± standard deviation of 0.88 ± 0.39 g/L) ([@B74]) with that of healthy adults and adult patients with CML.

The Advanced Dissolution, Absorption and Metabolism (ADAM) model ([@B29]) was used to describe imatinib absorption. The effective intestinal permeability (P~eff~) of imatinib was estimated using the apparent permeability data in Caco-2 cell lines (7.9 x 10^-6^ cm/s). P~eff~ was then utilized to predict the gut blood flow rate (Q~Gut~) ([@B111]). A whole-body PBPK model was used to describe the distribution of imatinib, with tissue-to-plasma partition coefficient (k~p~) values to each of the organs predicted *in silico* ([@B91]).

The intrinsic clearances (CL~int~) of imatinib to N-desmethyl imatinib (NDMI) and other metabolites were estimated from *in vitro* kinetic data using recombinant CYP3A4 (rCYP3A4) and human liver microsomes (HLM, in the presence of azamulin) as detailed in [**Table 1**](#T1){ref-type="table"} (unpublished). The latter represented the contribution of CYP2C8, since CYP enzymes other than CYP3A4 and CYP2C8 had a very minor contribution (3%) to imatinib metabolism ([@B38]). Biliary clearance (CL~bile~) of imatinib mediated by ABCB1 and ABCG2 transporters was parameterised by CL~int,T~ or J~max~ and K~m~ the values of which were extracted from previous *in vitro* studies ([@B28]; [@B19]). Relative activity factor (RAF) of ABCG2 transporter was adjusted to 0.38 to give a CL~bile~ of 28% of overall clearance of imatinib ([@B48]). The renal clearance value for imatinib (CL~R~ = 0.5 L/h) was taken from a study in patients with CML and Ph+ ALL ([@B18]). The CYP3A4-mediated formation clearance of metabolites other than NDMI (CLu~int,others,3A4~) was estimated from subtraction of depletion clearance of imatinib in rCYP3A4 enzyme (CLu~dep,3A4~) to formation clearance of NDMI in rCYP3A4 (CLu~int,NDMI,3A4~) as detailed in [**Table 1**](#T1){ref-type="table"}. Intersystem extrapolation factor (ISEF) of 0.21 ([@B22]) was used to correct for differences in intrinsic activity per unit enzyme between rCYP3A4 and HLM. Clearance of imatinib to other metabolites through a CYP2C8-mediated pathway was estimated according to Eq. 1.
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where CLu~int,total~ was back-calculated from *in vivo* apparent clearance (CL/F = 14.4 L/h) ([@B110]) after subtraction of CL~R~ using the well-stirred hepatic model (a retrograde approach) ([@B93]).

The mechanism-based inhibition (MBI) of CYP3A4 following a chronic use of imatinib was modeled by an enzyme turnover model as follows:
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where Enz~0~ and Enz~(t)~ indicate the amount of CYP3A4 (Enz) at baseline as reported previously ([@B27]) and at time t, respectively; k~deg~ represents the first-order degradation (turnover) rate constant of the enzyme in hepatocytes and enterocytes ([@B112]); k~inact~ denotes the maximum rate of inactivation, while K~Iu~ is imatinib concentration needed to reach half of k~inact~, both of which were obtained from a previous report ([@B37]); \[I\] and fu indicate imatinib concentrations in the liver or gut at time t and the unbound fraction of imatinib at the corresponding site of enzyme, respectively. Not accounting for CYP3A4 autoinhibition by imatinib at steady-state led to an overestimation of the extent of interaction with ritonavir, a CYP3A inhibitor, as summarized in [**Table S1**](#SM1){ref-type="supplementary-material"}. PBPK model predictions which incorporated a CYP3A4 MBI (Eq. 2) were consistent with the clinically observed interaction, however, CL/F of imatinib was underestimated ([**Table S1**](#SM1){ref-type="supplementary-material"}). A nonpathway specific additional clearance was assigned to the PBPK model at steady-state ([**Table 1**](#T1){ref-type="table"}) to correct this underprediction. This was also supported by a lack of significant changes in imatinib CL/F at steady-state compared to that on day 1 ([@B85]; [@B46]).

The importance of uptake transporter(s) has been hypothesized since imatinib is almost completely bioavailable, despite being a substrate of both ABCB1 and ABCG2 transporters ([@B10]). The activity of this uptake transporter seems to be diminished by coadministration of gemfibrozil ([@B39]) and in patients who had undergone major gastrectomy ([@B70]). However, available clinical evidence has been conflicting as to which transporter is primarily responsible for the uptake of imatinib ([@B82]; [@B10]). Coadministration of rifampicin, an inducer and inhibitor of CYP enzymes and SLCO1B transporters, respectively ([@B61]; [@B6]) at 600 mg/d for 7 days decreased systemic exposure (AUC~0-∞~) of imatinib given as a single 400 mg oral dose by 74% in healthy adults ([@B17]). This suggests that either the uptake process into the liver is not the rate-limiting step for hepatic metabolism of imatinib or sinusoidal uptake transporter(s) other than SLCO1B may play a role. However, the latter is unlikely given that clinical evidence of transporter-mediated drug interactions with imatinib as a victim drug is lacking. Therefore, transporter-mediated uptake processes in gut and liver were not included in the PBPK model.

PBPK simulations of imatinib in adults were performed with trial designs (number of people, age range, proportion of male/female, and dosing regimens) matched to the corresponding clinical studies ([**Table 2**](#T2){ref-type="table"}). A total of 10 virtual trials for each simulation were carried out. Clinically observed concentrations of imatinib were retrieved from the original publications using WebPlotDigitizer version 4.1 ([www.automeris.io/WebPlotDigitizer](www.automeris.io/WebPlotDigitizer)) and superimposed to simulated profiles to allow visual inspection of the predictive performance. Prediction differences of imatinib pharmacokinetic parameters, expressed as the ratio of PBPK model prediction to clinically reported parameter values were also evaluated.

###### 

Summary of clinical cohorts used for physiologically based pharmacokinetic (PBPK) model verification and comparison of simulated and clinically reported values for pharmacokinetic parameters of imatinib.

  Age range (years)                           Population                                                          Dosing regimens                                               Pharmacokinetic parameter   PBPK model prediction[^a)^](#fnT2_2){ref-type="table-fn"}   Clinically observed value                  Prediction fold-difference   Reference
  ------------------------------------------- ------------------------------------------------------------------- ------------------------------------------------------------- --------------------------- ----------------------------------------------------------- ------------------------------------------ ---------------------------- -------------------
  **Adult population**                                                                                                                                                                                                                                                                                                                          
  40--58                                      Healthy people (n = 12; 2 female)                                   400 mg, single-dose                                           C~max~ (µg/ml)              1.6                                                         1.8 ± 1.2                                  0.89                         ([@B83])
  t~max~ (h)                                  2.6                                                                 2.5 (1.0--6.0)                                                1.04                                                                                                                                                            
  AUC~0-∞~ (µg.h/ml)                          32.1                                                                32.6 ± 16.5                                                   0.98                                                                                                                                                            
  CL/F (L/h)                                  12.5                                                                14.9 ± 7.5                                                    0.84                                                                                                                                                            
  28--84                                      Patients with GIST (n = 34; 6 female)                               400 mg, day 1                                                 CL/F (L/h)                  11.2                                                        10.9[^b)^](#fnT2_3){ref-type="table-fn"}   1.03                         ([@B85])
  CV of CL/F (%)                              51                                                                  19[^c)^](#fnT2_4){ref-type="table-fn"}                                                                                                                                                                                        
                                                                                                                  400 mg/d, steady-state                                        CL/F (L/h)                  10.7                                                        10.9[^b)^](#fnT2_3){ref-type="table-fn"}   0.98                         
  CV of CL/F (%)                              54                                                                  19[^c)^](#fnT2_4){ref-type="table-fn"}                                                                                                                                                                                        
  39--82                                      Patients with GIST (n = 50; 21 female)                              400 mg/d, steady-state [^d)^](#fnT2_5){ref-type="table-fn"}   CL/F (L/h)                  9.6                                                         9.1[^b)^](#fnT2_3){ref-type="table-fn"}    1.05                         ([@B33])
  CV of CL/F (%)                              52                                                                  50[^c)^](#fnT2_4){ref-type="table-fn"}                                                                                                                                                                                        
  18--77                                      Patients with PAH (n = 103; 83 female)                              400 mg/d, steady-state                                        CL/F (L/h)                  9.8                                                         10.8[^b)^](#fnT2_3){ref-type="table-fn"}   0.91                         ([@B89])
  CV of CL/F (%)                              53                                                                  43[^c)^](#fnT2_4){ref-type="table-fn"}                                                                                                                                                                                        
  **Paediatric population**                                                                                                                                                                                                                                                                                                                     
  2--22[^e)^](#fnT2_6){ref-type="table-fn"}   Patients with GIST (n = 33; 13 female)                              340 mg/m^2^, day 1                                            CL/F (L/h)                  7.6                                                         7.8[^b)^](#fnT2_3){ref-type="table-fn"}    0.97                         ([@B85])
  CV of CL/F (%)                              69                                                                  19[^c)^](#fnT2_4){ref-type="table-fn"}                                                                                                                                                                                        
                                                                                                                  340 mg/m^2^, steady-state                                     CL/F (L/h)                  6.8                                                         7.8[^b)^](#fnT2_3){ref-type="table-fn"}    0.87                         
  CV of CL/F (%)                              75                                                                  19[^c)^](#fnT2_4){ref-type="table-fn"}                                                                                                                                                                                        
  6--24[^e)^](#fnT2_6){ref-type="table-fn"}   Patients with solid tumours and Ph+ leukaemia (n = 41; 14 female)   440 mg/m^2^, day 1                                            CL/F (L/h)                  10.1                                                        10.8[^b)^](#fnT2_3){ref-type="table-fn"}   0.94                         ([@B77])
  CV of CL/F (%)                              63                                                                  32[^c)^](#fnT2_4){ref-type="table-fn"}                                                                                                                                                                                        
                                              440 mg/m^2^, steady-state                                           CL/F (L/h)                                                    8.7                         10.8[^b)^](#fnT2_3){ref-type="table-fn"}                    0.81                                                                    
  CV of CL/F (%)                              62                                                                  32[^c)^](#fnT2_4){ref-type="table-fn"}                                                                                                                                                                                        
  4--17                                       Patients with CML (n = 26; 6 female)                                300 mg/m^2^, steady-state                                     C~min~ (µg/ml)              1.2                                                         1.4 ± 0.8                                  0.86                         ([@B53]; [@B101])
  6--15                                       Patients with Ph+ ALL (n = 4; 2 female)                             300 mg/m^2^, day 1                                            C~max~ (µg/ml)              3.3                                                         3.9 (2.7--5.1)                             0.85                         ([@B74])
  AUC~24~ (µg.h/ml)                           49                                                                  55 (37--74)                                                   0.89                                                                                                                                                            
                                                                                                                  300 mg/m^2^, steady-state                                     C~ss,max~ (µg/ml)           4.5                                                         6.1 (3.8--8.4)                             0.74                         
  AUC~24~ (µg.h/ml)                           59                                                                  73 (60--87)                                                   0.81                                                                                                                                                            
  2--18                                       Patients with tumours in CNS (n = 4; 1 female)                      300 mg bid, day 1 and steady-state                            C~max~ (µg/ml)              2.7                                                         2.5 (1.7--3.0)                             1.08                         ([@B13])
  C~min~ (µg/ml)                              3.9                                                                 3.3 (2.1--3.7)                                                1.18                                                                                                                                                            
                                              Patients with tumours in CNS (n = 1; no female)                     500 mg/d, day 1 and steady-state                              C~max~ (µg/ml)              5.4                                                         4.9                                        1.10                         
  C~24~ (µg/ml)                               0.9                                                                 0.9                                                           1.00                                                                                                                                                            
  C~min~ (µg/ml)                              2.1                                                                 2.1                                                           1.00                                                                                                                                                            

AUC~0-∞~, area under the plasma concentration-time curve from time zero to infinity; AUC~24~, area under the plasma concentration-time curve during 24 h after dose; C~24~, plasma concentration at 24 h; C~max~, peak plasma concentration; C~min~, trough concentrations; CNS, central nervous system; C~ss,max~, peak plasma concentration at steady-state; CL/F, apparent clearance; CML, chronic myeloid leukaemia; CV, coefficient of variation; GIST, gastrointestinal stromal tumours; PAH, pulmonary arterial hypertension; Ph+ ALL, Philadelphia chromosome-positive acute lymphoblastic leukaemia; t~max~, time required to achieve peak plasma concentration.

Reported as geometric mean values of PBPK model prediction.

Typical population value.

Based on ω (standard deviation of eta, interindividual variability) of apparent clearance.

26% of the cohort received 800 mg/d of imatinib.

This cohort also includes young adult patients.

Extrapolation of the PBPK Model of Imatinib to Paediatric Population {#s2_2}
--------------------------------------------------------------------

The verified PBPK model of imatinib in the adult population was extrapolated to children and adolescents (2--18 years) according to the best practice in development of paediatric PBPK model ([@B72]; [@B71]). Drug-specific parameters for imatinib were fixed at the same values as those defined in the adult PBPK model ([**Table 1**](#T1){ref-type="table"}). The algorithms for ontogeny profiles of CYP enzymes ([**Figure 2A**](#f2){ref-type="fig"}) are incorporated into Simcyp Simulator by default ([@B56]). A sigmoidal E~max~ model (Eq. 3), driven by postnatal age, adequately describes the maturation of CYP3A4 and CYP2C8. Parameters specific to each enzyme are summarized in [**Table 3**](#T3){ref-type="table"}.
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![Ontogeny profiles of drug-metabolising enzymes responsible for imatinib metabolism **(A)** and age-related changes in plasma concentration of α~1~-acid glycoprotein **(B)** and liver volume **(C)**.](fphar-10-01672-g002){#f2}

###### 

Parameters used in sigmoidal E~max~ functions to describe the maturation of drug-metabolising enzymes involved in imatinib metabolism.

  Parameter         Hepatic CYP3A4   Intestinal CYP3A4   Hepatic CYP2C8
  ----------------- ---------------- ------------------- ----------------
  Adult~max~        1.06             1.06                1.00
  PNA~50~ (years)   0.64             2.36                0.02
  F~birth~          0.11             0.42                0.30
  n                 1.91             1.00                1.00

Adult~max~, maximum fractional level of expression in adults; CYP, cytochrome P450, F~birth~, fraction of CYP enzymes at birth relative to adult; n, the Hill coefficient; PNA~50~, time to reach half of adult~max~.

where adult~max~ represents the maximum level of expression (as a fraction) of CYP enzymes in adult population; F~birth~ is the fraction of CYP enzymes at birth relative to adult; n denotes an exponent which is analogous to the Hill coefficient; PNA and PNA~50~ are postnatal age and the maturation half-life in years, respectively.

The ontogeny function derived for α~1~-acid glycoprotein (AAG) as shown in Eq. 4 and [**Figure 2B**](#f2){ref-type="fig"} was based on a limited set of data compiled from previously published reports ([@B56]) and as an update of McNamara and Alcorn's linear equation ([@B76]). Interestingly, this sigmoidal E~max~ model is very similar to the one generated recently from a larger meta-analysis in healthy people ([@B73]). Unbound fraction of imatinib in paediatrics (fu~ped~) was then estimated based on the ratio of plasma concentrations of AAG to that in the adult population (Eq. 5). Developmental changes in organ blood flow (as percent cardiac output to different organs) and organ size have been detailed previously ([@B56]). The changes in liver size with body surface area (BSA) are specified in Eq. 6 ([@B55]), where BSA (m^2^) was estimated from body weight and height of each individual ([@B32]). The associated changes in liver size based on age and sex are depicted in [**Figure 2C**](#f2){ref-type="fig"}.
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where PNA denotes postnatal age in years; AAG~adult~ and AAG~ped~ are plasma concentrations of AAG in adult and paediatric population, respectively; and fu~adult~ is the unbound fraction of imatinib in adults (mean value of 0.05).

Given the importance of ABCB1 and ABCG2 transporters on biliary excretion of imatinib ([@B10]), the maturation rates of these drug transporters need to be considered. The expression of hepatic and intestinal ABCG2 transporter was not affected by age ([@B86]; [@B24]), while there are conflicting data on developmental changes in protein expression of hepatobiliary ABCB1 transporter ([@B80]; [@B86]). However, the clinical pharmacokinetic data and PBPK simulations of digoxin, a probe drug for ABCB1, suggest a rapid maturation and attainment of adult levels of expression within first few months after birth ([@B57]). Therefore, no age-related change was assumed for ABCB1 transporter and the adult values, which is the default setting in Simcyp Simulator, were applied.

The PBPK model in paediatrics was verified using published, clinical pharmacokinetic data following single- and multiple-dosing regimens of imatinib. Simulations were performed (10 virtual trials for each simulation) with a trial design similar to the corresponding clinical studies as presented in [**Table 2**](#T2){ref-type="table"}. It is worth mentioning that the age range of participants in a number of clinical studies overlaps with that of young adults ([@B85]; [@B77]). However, this was acceptable since all ontogeny functions employed in the model followed a clear trajectory until adult age ([**Figure 2**](#f2){ref-type="fig"}).

PBPK Simulation to Evaluate Optimal Dosing Regimens for Imatinib in Paediatrics {#s2_3}
-------------------------------------------------------------------------------

The paediatric population was categorised into several age groups: preschool (2--5 years) and school-age children (6--11 years), and adolescents (12--17 years) ([@B14]). PBPK simulations of imatinib were performed using hypothetical multiple-dosing regimens given for 14 days (steady-state was assumed to be achieved within this time frame) with n = 100 (40% of female) for each age group. The male-to-female ratio was based on the value observed in paediatric patients, in which boys had an approximately 1.3-fold higher risk to be diagnosed with CML ([@B25]). BSA-normalized doses of imatinib of 170, 230, 340, and 460 mg in paediatrics corresponded to fixed doses of 300, 400, 600, and 800 mg in adults, respectively. The total daily doses of imatinib (in mg) for each age band were rounded to the closest 50 mg, a half-size of the smallest commercially available imatinib tablet as recommended in the clinical setting ([@B101]) and were capped at the equivalent adult doses. Potential differences of imatinib C~min~ across age bands were evaluated by a one-way analysis of variance (ANOVA) with Tukey post hoc test using GraphPad Prism version 7.02 (GraphPad Software, La Jolla, CA, USA).

PBPK Model Prediction of Drug Interactions With a Range of CYP3A Modulators {#s2_4}
---------------------------------------------------------------------------

### Verification of Paediatric PBPK Models for Carbamazepine, Ketoconazole, and Rifampicin {#s2_4_1}

The default PBPK models for carbamazepine, ketoconazole, and rifampicin in Simcyp Simulator were used ([@B4]; [@B69]). The predictive performance of the PBPK models in paediatric population need to be verified prior to their further use, since the original models were developed in adults. PBPK simulations for the three CYP3A modulators were carried out across different dosing regimens and age groups as detailed in [**Table 4**](#T4){ref-type="table"}, with a total of 10 virtual trials for each of the simulations. The predicted fold-differences of pharmacokinetic parameters for each compound, expressed as PBPK model prediction over the values reported in clinical studies were determined.

###### 

Comparison of physiologically based pharmacokinetic (PBPK) model prediction and clinically observed values for pharmacokinetic parameters of carbamazepine, ketoconazole, and rifampicin in paediatric population.

  Dosing regimens                                         Population                                                   Age range (years)                        Pharmacokinetic parameter   PBPK model prediction[^a)^](#fnT4_2){ref-type="table-fn"}   Clinically observed value                 Prediction fold-difference   Reference
  ------------------------------------------------------- ------------------------------------------------------------ ---------------------------------------- --------------------------- ----------------------------------------------------------- ----------------------------------------- ---------------------------- -----------
  **Carbamazepine**                                                                                                                                                                                                                                                                                                            
  300 mg bid, multiple-dose                               Patients with epilepsy (n = 52; 21 girls)                    2--21                                    CL/F (L/h)                  3.8                                                         3.6[^b)^](#fnT4_3){ref-type="table-fn"}   1.06                         ([@B20])
  CV of CL/F (%)                                          54                                                           52[^c)^](#fnT4_4){ref-type="table-fn"}                                                                                                                                                                  
  9.5 mg/kg bid, multiple-dose                            Patients with epilepsy (n = 21; 10 girls)                    4--13                                    C~ss,max~ (µmol/L)          40.2                                                        39.8 ± 10.0                               1.01                         ([@B34])
  C~min~ (µmol/L)                                         19.0                                                         21.5 ± 5.8                               0.88                                                                                                                                                           
  AUC~24~ (µmol.h/L)                                      742.3                                                        762.5 ± 163.2                            0.97                                                                                                                                                           
  **Carbamazepine-10,11-epoxide**                                                                                                                                                                                                                                                                                              
  9.5 mg/kg bid of carbamazepine, multiple-dose           Patients with epilepsy (n = 21; 10 girls)                    4--13                                    C~ss,max~ (µmol/L)          5.5                                                         6.0 ± 2.3                                 0.92                         ([@B34])
  C~min~ (µmol/L)                                         4.5                                                          4.0 ± 1.6                                1.13                                                                                                                                                           
  AUC~24~ (µmol.h/L)                                      121.4                                                        138.0 ± 48.9                             0.88                                                                                                                                                           
  **Ketoconazole**                                                                                                                                                                                                                                                                                                             
  5 mg/kg, single-dose                                    Patients with oral candidiasis (n = 12; 5 girls)             2--12.5                                  AUC~6~ (µg.h/ml)            17.5                                                        15.3 ± 2.7                                1.14                         ([@B45])
  4.8 mg/kg bid, multiple-dose                            Patients with candidiasis (n = 7; 3 girls)                   1--14                                    C~ss,max~ (µg/ml)           4.6                                                         3.5 ± 0.9                                 1.31                         ([@B7])
  AUC~12~ (µg.h/ml)                                       19.9                                                         13.6 ± 2.4                               1.46                                                                                                                                                           
  8.7 mg/kg/d, multiple-dose                              Patients with candidiasis (n = 4; 1 girl)                    1--12                                    C~ss,max~ (µg/ml)           8.1                                                         6.3 ± 1.7                                 1.29                         ([@B7])
  AUC~24~ (µg.h/ml)                                       34.9                                                         40.7 ± 8.7                               0.86                                                                                                                                                           
  **Rifampicin**                                                                                                                                                                                                                                                                                                               
  10 mg/kg, single-dose                                   Patients with impetigo or cellulitis (n = 21; 10 girls)      0.5--5                                   AUC~8~ (µg.h/ml)            47                                                          56                                        0.84                         ([@B75])
  300 mg/m^2^ (30-min i.v. infusion), single-dose         Patients with *H. influenzae* infections (n = 20; 9 girls)   0.25--3                                  C~max~ (µg/ml)              30.8                                                        27.4 ± 12.1                               1.12                         ([@B63])
  CL~i.v.~ (L/h/m^2^)                                     4.1                                                          3.7 ± 1.3                                1.11                                                                                                                                                           
  300 mg/m^2^ tid (30-min i.v. infusion), multiple-dose   Patients with staphylococcal infections (n = 12; 5 girls)    0.25--13                                 C~ss,max~ (µg/ml)           28.4                                                        25.9 ± 1.3                                1.10                         ([@B64])
  CL~i.v.~ (L/h/m^2^)                                     4.3                                                          4.0 ± 1.5                                1.08                                                                                                                                                           

AUC~6~, AUC~8~, AUC~12~, AUC~24~, area under the plasma concentration-time curve during 6, 8, 12 and 24 h after dose, respectively; bid, twice daily; C~max~, peak plasma concentration; C~min~, trough concentration; C~ss,max~, peak plasma concentration at steady-state; CL~i.v.~, clearance after intravenous administration; CL/F, apparent clearance; CV, coefficient of variation; tid, three times a day; i.v., intravenous.

Reported as geometric mean values of PBPK model prediction.

Typical population value.

Based on ω (standard deviation of eta, interindividual variability) of apparent clearance.

### Evaluation of PBPK Model Prediction of Interaction With Carbamazepine {#s2_4_2}

PBPK simulations were performed to predict the extent of interaction between carbamazepine and imatinib in adults (n = 63, age ranging from 19 to 69 years) ([@B87]) and paediatrics (a 12-year old male) ([@B103]). Designs of the clinical studies were replicated in the PBPK simulations, except for the latter which was carried out in a total of 100 subjects with age range of 11--13 years. This was necessary since the Simcyp Simulator does not allow the assignment of a single age value in a trial design. The goodness-of-fit of the PBPK predictions was evaluated via a visual inspection of the simulated pharmacokinetic profiles which were overlaid to imatinib concentrations observed in the clinical studies.

### Implementation of PBPK Modeling Approach to Evaluate Drug Interactions With CYP3A Modulators Across Different Age Bands {#s2_4_3}

To investigate the age-related changes in liability to CYP modulation, PBPK prediction of imatinib interactions with a set of CYP3A modulators, exemplified by carbamazepine, ketoconazole and rifampicin were conducted in adult and paediatric populations. The verified PBPK models in paediatrics were used, with the addition of CYP2C8 induction to the rifampicin model (maximum fold of induction (Ind~max~) = 6.27 and concentration that provides half of Ind~max~ (IndC~50~) = 0.1 µmol/L) ([@B88]). CYP2C8 induction was also incorporated to carbamazepine and its active metabolite, carbamazepine-10,11-epoxide with IndC~50~ and Ind~max~ for both compounds of 22 µmol/L and 3.5, respectively ([@B114]). The induction of CYP3A and CYP2C8 was modeled by an increase in protein synthesis (turnover) rate constant in hepatocytes and enterocytes according to an enzyme turnover model ([@B4]). Ketoconazole inhibits CYP3A4 and CYP2C8 competitively with an inhibitory constant (Ki~u~) of 15 nmol/L ([@B69]) and 2.2 µmol/L, respectively. PBPK simulations were carried out with n = 50 (40% of female) for each age band. Imatinib was given for 14 days with and without carbamazepine, ketoconazole or rifampicin. Imatinib was administered at a daily dose of 230 mg/m^2^ and 400 mg for paediatrics and adults, respectively. The typical maintenance dosing regimens were assigned for each CYP3A modulator based on age ranges. Potential changes in area under the plasma concentration-time curve (AUC) of imatinib for each age group on the last day was predicted.

Results {#s3}
=======

Development and Verification of a PBPK Model for Imatinib in Adults {#s3_1}
-------------------------------------------------------------------

The PBPK model was successfully predicted pharmacokinetic of imatinib following single- and multiple-dosing regimens in adults ([**Figures 3A--E**](#f3){ref-type="fig"}). Clinically observed concentrations of imatinib fell within 5^th^ to 95^th^ percentiles of the PBPK model simulated pharmacokinetic profiles. Interestingly, PBPK simulation of the study by Petain et al. were in close agreement with those predicted using a population pharmacokinetic approach ([@B85]) as shown in [**Figures 3B, C**](#f3){ref-type="fig"}. However, the observed interindividual variability of imatinib concentrations on day 1 appears to be underestimated ([**Figure 3B**](#f3){ref-type="fig"}). All the key pharmacokinetic parameters of imatinib were predicted within a 1.25-fold difference (range: 0.84--1.05).

![Comparison of physiologically based pharmacokinetic (PBPK) model prediction and clinically observed concentrations of imatinib in adult **(A**--**E)** and paediatric populations **(F**--**N)**. PBPK simulations are presented as mean simulated concentrations (blue line) with their 5^th^ to 95^th^ percentiles (grey area) in linear scale with the corresponding semi-logarithmic plots as insets. Dashed and dotted black lines represent maximum and minimum simulated concentrations, respectively. Clinical pharmacokinetic data (circles) are depicted as either individual data **(B**--**L, N)** or mean concentrations with whiskers as corresponding standard deviations **(A**, **M)**. Population pharmacokinetic predictions of imatinib concentration are shown by red line **(B**, **C)**. Bid, twice a day.](fphar-10-01672-g003){#f3}

Extrapolation of the PBPK Model of Imatinib to Paediatric Population {#s3_2}
--------------------------------------------------------------------

PBPK model predictions in paediatrics (2--18 years) were consistent with clinically observed pharmacokinetic data ([**Figures 3F--N**](#f3){ref-type="fig"}), although the interindividual variability of imatinib concentrations following single-doses of 300 ([@B74]), 340 ([@B85]) and 440 mg/m^2^ ([@B77]) appeared to be underpredicted. A number of the clinical pharmacokinetic data came from studies with sparse sampling points, e.g. restricted to imatinib C~min~ ([@B101]) or only 1--2 samples from few children ([@B13]). However, PBPK simulations were able to capture the overall trend observed in the corresponding clinical studies ([**Figures 3J, M, N**](#f3){ref-type="fig"}). All simulated pharmacokinetic parameters fell within 1.25-fold of those reported in clinical pharmacokinetic studies ([**Table 2**](#T2){ref-type="table"}), except for peak concentrations of imatinib at steady-state (C~ss,max~) in the study by [@B74].

PBPK Simulation to Evaluate Optimal Dosing Regimens for Imatinib in Paediatrics {#s3_3}
-------------------------------------------------------------------------------

The C~min~ targets of at least 1,000 ng/ml ([@B68]; [@B108]) and more strictly, between 1,000 and 3,200 ng/ml ([@B67]) were used for the simulations. PBPK simulations indicated that the variability of the attained C~min~ of imatinib was higher in the paediatric population at age 2 to 5 years and middle-aged adults compared to other age groups ([**Figure 4**](#f4){ref-type="fig"}). The mean C~min~ after a daily dose of 340 mg/m^2^ were predicted to be above the target concentration of 1,000 ng/ml irrespective of the age group. At a lower dose (230 mg/m^2^), imatinib C~min~ values were predicted to be lower than the predefined target concentration in a large subset of children above 5 years of age ([**Figure 4**](#f4){ref-type="fig"}). Statistical analysis of C~min~ of imatinib given at a daily dose of 230 and 340 mg/m^2^ in paediatrics (corresponded to 400 and 600 mg in adults, respectively) indicated that there was no significant difference among different age bands *(p* \> 0.01).

![Simulated trough concentrations (C~min~) of imatinib stratified by age bands following various dosing regimens. Simulated data are shown as mean (symbols) with whiskers correspond to standard deviations. The lower and upper limits of target C~min~ (1,000--3,200 ng/ml) are indicated by dashed black lines.](fphar-10-01672-g004){#f4}

PBPK Model Prediction of Drug Interactions With a Range of CYP3A Modulators {#s3_4}
---------------------------------------------------------------------------

Comparisons of the prediction interval (mean concentrations and 5^th^ to 95^th^ percentiles) with the clinically observed pharmacokinetic data for carbamazepine, rifampicin, and ketoconazole at various dosing regimens in paediatrics are presented in [**Figure 5**](#f5){ref-type="fig"}. Carbamazepine is primarily metabolised by CYP3A and CYP2C8 enzymes and thus, induces its own metabolism ([@B105]). Interestingly, accounting for CYP2C8 induction in the PBPK model of carbamazepine and its active metabolite (carbamazepine-10,11-epoxide) in paediatrics improved the predictions ([**Figures 5A--C**](#f5){ref-type="fig"}; PBPK simulations without CYP2C8 induction are not shown). Prediction differences for pharmacokinetic parameters of carbamazepine and its metabolite in the presence and absence of CYP2C8 autoinduction were within 1.25-fold (range: 0.88--1.13) and 1.5-fold (range: 0.89--1.45), respectively ([**Table S2**](#SM1){ref-type="supplementary-material"}). In line with that, the decrease of imatinib C~min~ when coadministered with carbamazepine ([**Figure 6A**](#f6){ref-type="fig"}) was better predicted by the PBPK model that incorporates CYP2C8 induction \[C~min~ ratio of 0.38 vs. 0.47, compared to the clinically reported value of 0.34 ([@B87])\]. Clinical pharmacokinetic data for the corresponding interaction in paediatrics are sparse, limited to imatinib concentrations from a child on day 1 and at steady-state in the presence of multiple-doses of carbamazepine ([@B103]). Despite that, the verified PBPK model of imatinib in paediatric population described the clinical interaction data with a good accuracy, as shown in [**Figures 6B, C**](#f6){ref-type="fig"}.

![Predicted pharmacokinetic profiles of carbamazepine **(A**--**B)** and its metabolite, carbamazepine-10,11-epoxide **(C)**, ketoconazole **(D**--**F)**; and rifampicin **(G**--**I)** in paediatrics. The predictions are depicted in linear scale with the corresponding semi-logarithmic plots as insets (blue line: mean, grey area: 5^th^ to 95^th^ percentiles). Clinically observed concentrations (circles) are presented either as individual data **(A)**, mean **(C)** or mean with the associated standard deviations **(B**, **D**--**I)**. Tid, three times a day.](fphar-10-01672-g005){#f5}

![Physiologically based pharmacokinetic (PBPK) model prediction of imatinib concentrations in the presence (blue line) and absence of carbamazepine (red line) in adults **(A)** and paediatric **(B, C)**. Prediction intervals (5^th^ to 95^th^ percentiles) for imatinib concentrations with and without carbamazepine are represented by light blue and pink area, respectively. Clinically observed data are represented by mean concentrations of imatinib alone (triangle) or with carbamazepine (circles) with whiskers as corresponding standard deviations.](fphar-10-01672-g006){#f6}

In addition to carbamazepine, the PBPK model was also implemented for prediction of interactions with ketoconazole and rifampicin across different age groups (2--65 years). Predicted AUC ratios of imatinib in the presence and absence of each of the modulators are summarized in [**Figure 7**](#f7){ref-type="fig"}. It is noteworthy that the administration CYP3A modulators at their typical maintenance dosing regimens according to age bands yielded C~ss,max~ that were comparable across all groups, except for rifampicin, where C~ss,max~ was around 30% lower in middle-aged adults compared to children less than 18 years ([**Figure 7**](#f7){ref-type="fig"}). This was important to evaluate the extent of interactions among different age groups without being confounded by steady-state concentrations of the modulators. Further statistical analysis suggested that there were no significant differences in the extent of interactions between different age bands (one-way ANOVA followed by a Tukey post-hoc analysis, *p* \> 0.01).

![Physiologically based pharmacokinetic (PBPK) prediction of imatinib interactions with a set of CYP3A modulators (carbamazepine, ketoconazole, and rifampicin) at steady-state across different age bands. Imatinib at daily doses of 400 mg and 230 mg/m^2^ was administered to adult and paediatric populations, respectively along with CYP3A modulators for 14 days. The extent of interactions was evaluated based on AUC ratio metric (ratio of area under the plasma concentration-time curve of imatinib in the presence and absence of CYP3A modulators). Symbols represent median simulated AUC ratio with whiskers crossing from 5^th^ to 95^th^ percentiles. C~ss,max~, peak concentration at steady-state. AUC ratio of 1 (dotted black line) indicates absence of drug interactions with imatinib. Typical dosing regimens and the attained C~ss~,~max~ of the modulators for each age band in the PBPK simulations are also detailed.](fphar-10-01672-g007){#f7}

Discussion {#s4}
==========

We developed a PBPK model for imatinib in adult populations and extrapolated its use to paediatrics. The PBPK model was able to describe imatinib pharmacokinetics in both populations and had a capability to predict drug interactions with a range of CYP3A modulators.

A paediatric PBPK model for imatinib has been reported previously in a regulatory document submitted to [@B35]. Unfortunately, a lack of details regarding this PBPK model's structure and parameters limits its further use and interpretation. The PBPK model in the current study was verified to a larger set of clinically published pharmacokinetic data and its implementation was extended to predict drug interactions in paediatrics.

Scaling drug doses from adults to children is far from a straightforward process ([@B60]). Both population pharmacokinetic and PBPK approaches have been used independently or in combination to guide drug dosing in paediatric patients ([@B59]). A population pharmacokinetic model incorporating body weight as a primary covariate with an allometric exponent, e.g. ¾ for clearance, often does not perform well in infants and young children due to maturation of drug eliminating processes ([@B43]). In most cases, the predictions are improved by employing a sigmoidal ontogeny function driven by postmenstrual age ([@B5]). However, the maturation half-life and Hill coefficient which parameterise the function vary across different drugs ([@B52]; [@B43]) and thus, sufficient number of individuals with age around the maturation half-life is necessary for precise parameter estimation. PBPK modeling and simulation offers an alternative approach to evaluate an optimal dosing regimen in the paediatric population. It integrates drug-specific inputs and system-related parameters, the latter of which encompass developmental changes in physiology and maturational rates of drug-metabolising enzymes and proteins involved in drug disposition ([@B71]). This approach enables extrapolation from adults or between age groups within paediatric populations and increases the mechanistic understanding of potential sources of interindividual variability in systemic exposure to a drug.

The ontogeny profiles of key CYP enzymes responsible for imatinib metabolism ([**Figure 2**](#f2){ref-type="fig"}) are based on a meta-analysis of *in vitro* CYP activity in post-mortem livers of donors from different ages ([@B56]). The maturation functions tend to underestimate the apparent clearance of CYP3A substrates in neonates and infants ([@B96]). Two *in vivo*-derived algorithms have been proposed to improve the prediction ([@B96]; [@B106]). The Upreti and Wahlstrom model for CYP3A4 maturation has been shown to perform better with less underprediction of clearance ([@B58]). However, as expected, the PBPK simulations that implemented this ontogeny for children older than 2 years of age yielded a similar result to that of *in vitro* maturation function (results not shown). Therefore, the latter, which is incorporated in the Simcyp Simulator (version 17) by default, was utilized throughout the simulations. Developmental changes in organ size, particularly liver volume were also incorporated in the PBPK model. Liver volume was most parsimoniously described by a nonlinear regression against BSA as shown in Eq. 6 ([@B55]). Interestingly, this equation was in concordance with an allometric weight model with an exponent of ¾ in estimating liver volume from infants to adolescents ([@B36]). The correlation between liver volume and BSA alone was superior than that with other covariates ([@B55]), in agreement with the findings of a nonlinear mixed effect modeling approach ([@B99]). All the ontogeny equations used in the current study were driven by postnatal age. Postmenstrual age is more useful if preterm neonates are included in PBPK simulations ([@B1]; [@B44]).

It is noteworthy that the PBPK models may overestimate clinically observed peak plasma concentrations (C~max~) since they report predicted concentrations at the central venous compartment rather than the peripheral vein from which blood (plasma) samples were collected. This is particularly important for intravenous (i.v.) administration routes where a substantial amount of drug is delivered to central venous compartment directly and equilibration to the peripheral venous sites may not be instantaneous ([@B81]). A PBPK model prediction of drug concentrations at a peripheral sampling site based on contributions from surrounding tissues (e.g., adipose, muscle, and skin) as proposed by [@B81] has proven to be useful to correct the PBPK predictions at initial time following i.v. administrations. As depicted in [**Figure S1**](#f1){ref-type="fig"}, implementation of this strategy within the Simcyp Simulator improved the PBPK model predictions of C~max~ following a 1-h infusion of imatinib (100 mg) ([@B83]) compared to that of central venous compartment (prediction differences of imatinib C~max~ of 0.99 vs. 1.42). Prediction differences for other pharmacokinetic parameters of imatinib were similar between the two strategies (results not shown). Conversely, the peripheral sampling site model has little to no effect on PBPK predictions of C~max~ of imatinib given orally (results not shown). Unlike i.v. administration over a short period of time, oral administrations of drugs are likely to give sufficient time for central venous compartment (pooled venous return) and peripheral vein in the arm to equilibrate ([@B81]).

The observed interindividual variability of imatinib concentrations in children on day 1 appeared to be higher than that at steady-state from the corresponding patient cohort ([**Figures 3F--I**](#f3){ref-type="fig"}). The reason for this trend was not clear, but may be related to a lower between individual variability in CYP3A4 activity due to the autoinhibition by imatinib following chronic exposure ([@B37]; [@B38]). PBPK simulations also highlighted a higher interindividual variability of imatinib concentrations at a fixed daily dose compared to a BSA-normalized dosing regimen ([**Figures 3M, N**](#f3){ref-type="fig"} vs. [**3F--L**](#f3){ref-type="fig"}). A daily dose administered on a mg/m^2^ basis in paediatric populations is usually preferred to body weight-based and flat-fixed dosing regimens owing to more favorable pharmacokinetic variability, particularly over a wide age range ([@B11]; [@B51]).

A clear exposure-response relationship for imatinib has not been established in younger patients with CML. Thus, the proposed targets in children and adolescents were based on the concentration known to be safe and efficacious in adults (C~min~ ranging from 1,000 to 3,200 ng/ml ([@B67])). This was further supported by the similar biological and clinical features of CML observed in adult and younger patients ([@B9]), with only a slight difference, particularly a higher leukocyte count presented in the latter ([@B78]). Paediatric and adult patients also had comparable response and safety profiles (e.g., occurrence of grade 3/4 haematological toxicities and musculoskeletal adverse events) to an equivalent dose of imatinib ([@B79]). This was not the case for solid tumours harboring mutations in the gene that encodes tyrosine kinase KIT (e.g. GIST). Imatinib exerted minor anticancer activity in children with GIST compared to the adult cohort, despite similar systemic concentrations ([@B42]).

The observed trend of a higher interindividual variability of simulated C~min~ in children aged between 2 and 5 years and middle-aged adults compared to other age groups ([**Figure 4**](#f4){ref-type="fig"}) was likely attributed to a higher variability within these age bands due to maturational changes of CYP enzymes that have not attained adult levels of expression ([@B56]) and a reduction of total hepatic clearance related to a decrease of liver weight and scaling factor (e.g., microsomal protein per gram of liver/MPPGL) ([@B12]; [@B23]), respectively.

PBPK simulations suggested a similar C~min~ following imatinib doses of 230 and 340 mg/m^2^/d in paediatrics and 400 and 600 mg/d in adult population, respectively *(p* \> 0.01). This was in agreement with the finding in clinical studies in children with Ph+ leukaemias or GIST which indicated a similar systemic exposure of imatinib at daily doses of 230 and 340 mg/m^2^ compared to those of adult patients treated with 400 and 600 mg/d of imatinib, respectively ([@B21]; [@B42]). The C~min~ target of 1,000 ng/ml was predicted to be attainable by a 230 mg/m^2^/d dose in paediatric age groups (similar to an adult dose of 400 mg/d), albeit with a large subset of the population below the target. Due to this variability, a higher dose of 340 mg/m^2^/d (corresponds to an adult dose of 600 mg/d) might be needed. This was in line with the recommendation for the treatment of CML in children with the recommended initial doses of 260--300 mg/m^2^/d and 400 mg/m^2^/d for chronic and accelerated phases, respectively ([@B30]).

There was a good agreement between PBPK model prediction and clinically observed changes in imatinib concentrations due to the coadministration of carbamazepine in adult and paediatric populations ([**Figure 6**](#f6){ref-type="fig"}). It should be noted that clinical pharmacokinetic data in the latter came from one Japanese paediatric patient (a case study) ([@B103]). PBPK simulations in paediatrics refer to European ancestry, from which the ontogeny functions for drug-metabolising enzymes and AAG were derived ([@B56]). However, our previous simulation study suggested little to no difference in imatinib pharmacokinetic between people from Japanese and European ancestry (unpublished).

Clinical drug-drug interaction (DDI) data in adults may not be suitable for extrapolation across all paediatric age bands ([@B95]; [@B97]). The magnitudes of enzyme-based DDI are dictated by the level of contribution (f~m~) and maturational rates of corresponding CYP enzymes ([@B94]). In this study, a PBPK modeling approach was utilized to evaluate drug interactions with imatinib in paediatrics. The trend and extent of interactions between imatinib and CYP3A modulators (carbamazepine, rifampicin and ketoconazole) were predicted to be similar between paediatric and adult populations, despite a slight difference in the simulated means and interindividual variabilities ([**Figure 7**](#f7){ref-type="fig"}). Imatinib inhibits its own CYP3A4-mediated metabolism following multiple-dosing regimen ([@B37]). Thus, the effect of CYP3A modulators on imatinib metabolism was likely to be diminished following a long-term use of imatinib, as observed in a clinical interaction study between imatinib and ritonavir ([@B107]). The extent of modulation by CYP3A inhibitors, either direct (reversible) or mechanism-based inhibitors, e.g., ketoconazole and ritonavir, respectively was predicted to be more affected following repeated-dose administration of imatinib, compared to that observed with CYP3A inducers (e.g., rifampicin and carbamazepine). This was due to limited residual CYP3A activity which can further be inhibited in the former. Since imatinib undergoes little to no metabolism in the enterocytes ([@B10]), inducers of CYP3A confined to intestinal enzymes (e.g., hyperforin in St John's wort) are unlikely to affect steady-state CL/F of imatinib ([@B2]).

The limitation of this study is a lack of specific maturation functions for children with cancer implemented in the PBPK model. The trend of developmental changes in organ size, CYP enzymes and plasma proteins observed in healthy children may not hold true for the paediatric cancer population ([@B104]). A further limitation to this study is the exclusion of children less than 2 years of age from the simulations ([**Figures 4**](#f4){ref-type="fig"} and [**7**](#f7){ref-type="fig"}) due to a paucity of clinical pharmacokinetic data for this age group (CML is exceptionally rare in very young children ([@B30])). Moreover, there is a high uncertainty in the maturation pattern of CYP3A4 in this challenging age group ([@B58]), which is further complicated by the potential presence of CYP3A7 enzyme. The latter is absent in adults, but expressed at a high level during foetal life and decreases progressively throughout the first 2 years after birth ([@B3]). A further study to elucidate CYP3A7 contribution to imatinib metabolism is necessary in order to perform a PBPK prediction with confidence in children less than 2 years.

In conclusion, a PBPK model for imatinib was successfully developed in adults and extrapolated to the paediatric population. The PBPK model was able to describe clinical pharmacokinetic data from published studies observed in adults, children and adolescents. PBPK simulation suggested an optimal dosing regimen range for imatinib of 230--340 mg/m^2^/d in paediatrics, in concordance with the recommended initial dose for treatment of childhood CML. The simulations also highlighted that children and adults being treated with imatinib have similar vulnerability to drug interactions that modulate drug metabolising enzyme activity. These findings suggest that at steady-state, imatinib is more susceptible to hepatic induction compared to inhibition of CYP3A enzymes.
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